VALENS GROWORKS ADDED TO CSE25 INDEX
Vancouver, B.C., November 1, 2017 – Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”), a biotechnology company specializing in the research, development and commercialization of novel, cannabinoid- based products and drug therapies, is pleased to announce its inclusion in the CSE25 Index. The CSE25 Index is a subgroup of the CSE Composite Index that recognizes the highest achievers listed on the CSE. Valens qualified for the index as one of the twenty-five largest companies in the CSE Composite Index.
About the CSE25 Index
The Canadian Securities Exchange (“CSE“) recently announced the introduction of the CSE25 Index, comprised of the securities of the largest companies trading on the exchange. The CSE25 Index is a subgroup of the CSE Composite Index. The composite index launched in 2015 and includes almost half of the exchange’s listed companies and, according to the CSE, covers over 75% of the trading activity on the exchange. The new index includes the top twenty-five securities by market capitalization contained in the composite index. According to the CSE, these companies account for over 50% of the weighting in the larger index and are typically stocks that attract considerable trading volume.
About Valens GroWorks Corp.
Valens GroWorks Corp. is a biotechnology company with an aggressive buildout strategy. The Company seeks to capture a broad spectrum of medical cannabis users, and adult recreational users once legalized, as well as clinical trial and R&D clients, in pursuit of its ambitious “plants to premium products” objectives.
The Company operates a 17,000 square foot facility located on two acres in Kelowna, in the heart of British Columbia’s Okanagan Valley. Wholly owned subsidiary Supra THC Services Inc. (“Supra”), in collaboration with Thermo Fisher Scientific, a world leader in Health Science services, is developing a “Centre of Excellence in Plant Based Medicine Analytics” to provide analytical services and directed research and development, including clinical trials. Supra and the Company’s subsidiary Valens AgriTech Ltd. (“Valens AgriTech”), a Health Canada Licensed Dealer, recently announced a $330,000 MITACS funded research grant and collaboration with UBC Okanagan and Thompson Rivers University to explore potential cannabis bio-products including pharmaceuticals, nutritional products, and industrial fiber.
For more information, visit www.valensgroworks.com
On behalf of the Board of Directors, VALENS GROWORKS CORP.
(signed) “Rob van Santen”
Chief Financial Officer
For further information, please contact:
Notice regarding Forward Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections
contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.